Pages that link to "Q415159"
Jump to navigation
Jump to search
The following pages link to rosuvastatin (Q415159):
Displayed 50 items.
- arteriosclerosis (Q184559) (← links)
- heart disease (Q190805) (← links)
- acenocoumarol (Q304088) (← links)
- (S)-(−)-colchicine (Q326224) (← links)
- cyclosporine (Q367700) (← links)
- gemfibrozil (Q384295) (← links)
- 3-hydroxy-3-methylglutaryl-CoA reductase (Q415607) (← links)
- (2R)-daptomycin (Q418747) (← links)
- fenofibrate (Q419724) (← links)
- lopinavir (Q422585) (← links)
- ritonavir (Q422618) (← links)
- saquinavir (Q422654) (← links)
- atazanavir (Q423467) (← links)
- bezafibrate (Q577387) (← links)
- fosamprenavir (Q1385311) (← links)
- lipid metabolism disorder (Q1476525) (← links)
- familial hypercholesterolemia (Q2711291) (← links)
- ciprofibrate (Q3496452) (← links)
- AURORA trial (Q4654994) (← links)
- atherosclerosis (Q12252367) (← links)
- ledipasvir (Q15409409) (← links)
- rosuvastatin calcium (Q27146836) (← links)
- (3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-yl-5-pyrimidinyl]-3,5-dihydroxy-6-heptenoic acid (Q27165152) (← links)
- Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndrome (Q36807515) (← links)
- Managing hypercholesterolemia and preventing cardiovascular events in elderly and younger Chinese adults: focus on rosuvastatin (Q37388209) (← links)
- A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine (Q37470663) (← links)
- Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy (Q37528422) (← links)
- Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin (Q38155218) (← links)
- A meta-analysis of randomized head-to-head trials for effects of rosuvastatin versus atorvastatin on apolipoprotein profiles (Q38162582) (← links)
- Pharmacodynamic effects of atorvastatin versus rosuvastatin in coronary artery disease patients with normal platelet reactivity while on dual antiplatelet therapy--the PEARL randomized cross-over study (Q38437519) (← links)
- Impact of switching treatment from rosuvastatin to atorvastatin on rates of cardiovascular events (Q38451069) (← links)
- NLRP3 inflammasome activation in coronary artery disease: results from prospective and randomized study of treatment with atorvastatin or rosuvastatin (Q39110336) (← links)
- Vascular damage in testicular cancer patients: a study on endothelial activation by bleomycin and cisplatin in vitro. (Q39767766) (← links)
- Rosuvastatin attenuates Ang II--mediated cardiomyocyte hypertrophy via inhibition of LOX-1. (Q43282310) (← links)
- Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome (Q43841734) (← links)
- Effect of rosuvastatin therapy on troponin I release following percutaneous coronary intervention in nonemergency patients (from the TIP 3 study). (Q44550500) (← links)
- Rosuvastatin inhibits human airway smooth muscle cells mitogenic response to eicosanoid contractile agents. (Q45984649) (← links)
- Vascular and neural dysfunction in Zucker diabetic fatty rats: a difficult condition to reverse. (Q46923585) (← links)
- Crestor (Q47521418) (← links)
- Rosuvastatin attenuates atherosclerosis in rats via activation of scavenger receptor class B type I. (Q48032769) (← links)
- Rationale and design of the EPISTEME trial: efficacy of post-stroke intensive rosuvastatin treatment for aortogenic embolic stroke. (Q48974343) (← links)
- Mevalonate arm of cholesterol biosynthesis pathway with inhibitors (Q50399861) (← links)
- Anti-sympathetic action enhances statin's pleiotropic effects: the combined effect of rosuvastatin and atenolol on endothelial function. (Q53634869) (← links)
- rare dyslipidemia (Q55785266) (← links)
- Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease (Q57097296) (← links)
- Rosuvastatin Can Block Pro-Inflammatory Actions of Transgenic Human C-Reactive Protein Without Reducing its Circulating Levels (Q57652163) (← links)
- (E,3R,5R)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid (Q63392169) (← links)
- Pharmacokinetic comparison of a fixed-dose combination versus concomitant administration of amlodipine, olmesartan, and rosuvastatin in healthy adult subjects (Q64079467) (← links)
- Author's reply to uses of clopidogrel, rosuvastatin and digoxin on the risk of acute pancreatitis (Q64110136) (← links)
- Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial (Q86057032) (← links)